Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Attends 31st Annual ROTH Conference
Tonix Pharmaceuticals Holding (NASDAQ: TNXP) is a clinical-stage biopharmaceutical company focused on discovering and developing pharmaceutical products to treat serious neuropsychiatric conditions and biological products to improve biodefense through potential medical counter-measures. Tonix is developing Tonmya, which is in phase 3 development and has been granted Breakthrough Therapy designation by the FDA, as a bedtime treatment for PTSD. Tonix is also developing TNX-102 SL as a bedtime treatment for agitation in Alzheimer’s disease under a separate IND to support a phase 2, potential pivotal, efficacy study and has been designated a Fast Track development program by the FDA for this…







